Filing identity and reporting period
The supplied filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2018—not a Neurogene Inc. filing. The company described itself as a pharmaceutical developer; it reported no product candidates in clinical development or identified for clinical development after halting rosiptor development.
Financial results and liquidity
| Metric | Three months ended September 30, 2018 | Nine months ended September 30, 2018 |
|---|---|---|
| Revenue | $0 | $25.0 million |
| Operating expenses | $15.2 million | $52.3 million |
| Net loss | $15.0 million | $26.7 million |
| Net loss per share, basic and diluted | $0.64 | $1.14 |
| Cash used in operating activities | Not provided for the quarter | $21.8 million |
Nine-month revenue was the non-refundable $25.0 million upfront payment under the Astellas license agreement; it was not recurring product revenue. At September 30, cash and cash equivalents were $86.7 million, versus $52.0 million at December 31, 2017. Working capital was $76.5 million; total liabilities were $11.1 million, including $10,000 of capital lease obligations. No material debt financing was reported. The company said its existing capital was expected to fund operations for at least 12 months, while also anticipating substantial future financing needs.
Changes versus comparable periods
- Third-quarter operating expenses rose to $15.2 million from $12.1 million in 2017, and net loss widened to $15.0 million from $11.8 million.
- For the first nine months, operating expenses increased to $52.3 million from $34.6 million, while net loss narrowed to $26.7 million from $33.9 million, primarily reflecting the $25.0 million Astellas payment.
- Nine-month research and development expense increased to $39.2 million from $24.7 million; general and administrative expense increased to $13.1 million from $9.9 million.
- Operating cash use declined to $21.8 million from $33.1 million. Investing cash inflow of $56.0 million primarily reflected maturities of short-term investments, rather than operating cash generation.
Outlook, material events and risks
- Rosiptor’s Phase 3 Leadership 301 trial failed its primary endpoint; the company halted further development. Astellas gave notice that it would terminate the license agreement effective March 4, 2019, unless the parties agreed to an earlier date. The upfront payment is non-refundable; potential future milestones and royalties were uncertain.
- The July restructuring reduced the workforce by 30 employees, approximately 53%, and closed the San Bruno office. Estimated charges were $9.2 million, of which $3.3 million was paid in the quarter and $5.6 million remained accrued at September 30; most accrued amounts were expected to be paid by year-end.
- On November 6, 2018, the board approved a further workforce reduction of 16 employees, including the Chief Operating Officer, effective December 31. The company estimated about $1.0 million in related 2018 charges and said further staff reductions could occur in 2019. After both plans, the workforce was expected to fall from 56 to 8.
- Management was evaluating strategic options and expected R&D expense to decline as rosiptor trial closeout activities finished. The filing did not provide a specific earnings or revenue forecast.
- Key risks include lack of recurring revenue and a clinical pipeline, continued losses, need for additional capital on potentially unavailable or unfavorable terms, execution of restructuring and strategic plans, and loss of key staff. The company reported no material change in internal control over financial reporting; disclosure controls were considered effective at a reasonable assurance level.
Investor facts to verify
- Confirm the issuer identity: this text is Aquinox Pharmaceuticals’ filing, inconsistent with the Neurogene Inc. metadata.
- Check the Astellas termination status and any later agreement, milestone, royalty, or payment obligations.
- Assess cash runway using post-quarter restructuring costs and the reduced workforce, rather than relying solely on the stated 12-month estimate.
- Review subsequent strategic, financing, or asset-transaction developments, given the absence of a clinical-stage product candidate.
- Reconcile the restructuring estimates, accrued liabilities, and expected payments with subsequent filings.